奕瑞电子科技集团股份有限公司（以下简称"公司"）于 2025 年 6 月 6 日收 到上海证券交易所出具的《关于上海奕瑞光电子科技股份有限公司向特定对象发 行股票的交易所审核意见》，具体意见如下： "上海奕瑞光电子科技股份有限公司向特定对象发行股票申请符合发行条件、 上市条件和信息披露要求。本所将在收到你公司申请文件后提交中国证监会注 册。" | 证券代码：688301 | 证券简称：奕瑞科技 公告编号：2025-038 | | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | 奕瑞电子科技集团股份有限公司 关于 2024 年度向特定对象发行 A 股股票申请收到 上 海证券交易所审核通过的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特此公告。 奕瑞电子科技集团股份有限公司董事会 2025 年 6 月 7 日 公司本次向特定对象发行 A 股股票事项尚需经中国证券监督管理委员会（以 下简称"证监会"）作出同意注册的决定后方可实施，最终能否获得证监会同意注 册的决定及其时间尚存在不确定性。 ...

因实施 2024 年年度权益分派，奕瑞电子科技集团股份有限公司（以下简称"公司"） 的相关证券停复牌情况如下：权益分派公告日前一交易日（2025 年 6 月 12 日）至 权益分派股权登记日期间，公司可转债将停止转股。 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 期间 | | | | 118025 | 奕瑞转债 | 可转债转股停 | 2025/6/12 | | | | | | | 牌 | | | | | | 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-037 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于实施 2024 年年度权益分派时可转债转股价格调整 暨转股连续停牌的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ...

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which has shown a 4.01% increase over the past month, a 0.74% decrease over the past three months, and a 1.94% increase year-to-date [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huitai Medical (10.98%), United Imaging (10.82%), Aibo Medical (6.74%), Yirui Technology (6.5%), Nanwei Medical (5.36%), Shengxiang Biology (4.94%), Xinmai Medical (4.68%), Haier Biomedical (4.22%), Yahui Long (3.6%), and Aohua Endoscopy (3.4%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100.00% share [1] - The industry composition of the index holdings includes 45.00% in medical consumables, 33.89% in medical devices, and 21.10% in in vitro diagnostics [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are adjusted in accordance with the sample adjustments, which occur at the same time as the sample adjustments [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

Core Insights - The CT tube, also known as X-ray tube, is a critical component of CT equipment, directly affecting imaging quality, scanning speed, and equipment lifespan [1][9] - The cost of CT tubes accounts for approximately 20% of the total production cost of CT devices, and they have a shorter lifespan compared to the devices themselves, necessitating regular replacements [9][11] - The demand for CT tubes in China is driven by both new installations of CT devices and the maintenance of existing units, with the market capacity expected to grow significantly in the coming years [9][11] Market Capacity and Structure - In 2024, the market capacity for CT tubes in China is projected to be 35,396 units, consisting of 25,835 units from the existing market and 9,561 units from new installations [9][11] - By 2025, the market capacity is expected to reach 40,445 units, with 30,000 units from the existing market and 10,445 units from new installations [9][11] - The demand for replacement tubes due to maintenance will surpass the demand from new installations as the number of CT devices increases [9][11] Industry Development Environment - The Chinese government has implemented supportive policies for the development of high-end medical equipment and key components, including CT tubes, as part of the "14th Five-Year Plan" [4][6] - Policies encourage innovation and the enhancement of manufacturing capabilities in the medical equipment sector, particularly for CT technology [4][6] Current Industry Status - The CT equipment stock in China is expected to reach 51,670 units in 2024, with an increase of 9,561 units, and approximately 60,000 units by 2025, with an increase of 10,445 units [7] - The rapid development of the CT and medical imaging equipment industry is driven by increasing market demand and the need for domestic alternatives to imported products [7][9] Competitive Landscape - Key players in the CT tube market include companies such as United Imaging, Neusoft Medical, and others, with significant investments in R&D for domestic CT tube production [14][15] - Despite advancements in domestic production, there remains a gap between local suppliers and international manufacturers in terms of technology and manufacturing processes [14][15] Industry Trends - The CT tube industry is entering a critical development phase due to accelerated domestic production, technological upgrades, and growing demand [18] - The average lifespan of a CT tube is about 13 months, indicating a high replacement frequency during the lifespan of a CT device, which typically exceeds 10 years [11]

公司代码：688301 公司简称：奕瑞科技 2025 年第二次临时股东大会会议资料目录 | 2025 | 年第二次临时股东大会会议须知 3 | | --- | --- | | 2025 | 年第二次临时股东大会会议议程 5 | | 2025 | 年第二次临时股东大会会议议案 7 | | | 议案一：关于新增 2025 年度关联交易预计的议案 7 | | | 议案二：关于对全资子公司增资暨对外投资的议案 11 | 奕瑞电子科技集团股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 6 月 1 / 14 奕瑞电子科技集团股份有限公司 2025 年第二次临时股东大会会议资料 奕瑞电子科技集团股份有限公司 2 / 14 奕瑞电子科技集团股份有限公司 2025 年第二次临时股东大会会议资料 奕瑞电子科技集团股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保奕瑞电子科技集团股份有限公司（以下 简称"公司"）股东大会的正常秩序和议事效率，保证大会的顺利进行，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《奕 ...

Core Viewpoint - Yirui Technology (688301.SH), a domestic core component supplier for medical imaging, is accelerating its industrial layout through an investment of up to 1.8 billion yuan in a silicon-based OLED microdisplay backplane production project [1][2]. Investment and Expansion - The company plans to increase its investment in its wholly-owned subsidiary, Yirui Imaging Technology (Hefei) Co., Ltd., by 600 million yuan to implement the silicon-based OLED microdisplay backplane production project [2][3]. - The project aims to add a production capacity of 5,000 units per month, with a construction period of 12 months and an expected payback period of 6.7 years, yielding an internal rate of return of 11.01% [2][3]. R&D Investment - From 2020 to 2024, Yirui Technology's cumulative R&D investment reached 1.053 billion yuan, with annual investments showing a growth trend: 96 million yuan in 2020, 146 million yuan in 2021, 239 million yuan in 2022, 262 million yuan in 2023, and 310 million yuan in 2024 [3][4]. Market Position and Performance - Yirui Technology is a leading player in the digital X-ray detector market, with production bases located in Shanghai, Jiangsu, Zhejiang, and Seoul, South Korea [4]. - In 2024, the company reported a revenue of 1.831 billion yuan, a year-on-year decrease of 1.74%, and a net profit of 465 million yuan, down 23.43% [5][6]. Globalization Efforts - In 2024, Yirui Technology enhanced its global presence by establishing sales or customer service platforms in the United States, Germany, and South Korea [6]. - The company also plans to issue shares to specific investors to raise funds for the construction of X-ray vacuum devices and comprehensive solution projects, which will add significant production capacity [6].

Core Viewpoint - The article discusses the rising investment in the Micro OLED sector driven by the increasing demand for AR glasses and the establishment of new production projects by various companies in the industry [1][11]. Company Investment - Yisui Technology plans to invest up to 1.8 billion yuan in a Micro OLED micro-display backplane production project, with an additional 600 million yuan allocated to its wholly-owned subsidiary, Yisui Imaging Technology (Hefei) [2][5]. - The project aims to add a production capacity of 5,000 units per month to meet specific customer demands, particularly from Shiya Technology [5][6]. Industry Development - The Micro OLED sector is experiencing a surge in project launches, with multiple companies, including Hongxi Technology and Xitai Technology, announcing significant investments and new production lines [7][9]. - Shiya Technology currently operates a 12-inch evaporation line capable of producing 9,000 wafers per month, with plans to expand to three lines producing 27,000 wafers per month [7][10]. Market Demand - The demand for Micro OLED displays is expected to grow, particularly in AR glasses, where it is projected to account for 54% of the market share by 2024 [10]. - Micro OLED technology is also anticipated to find applications in various fields, including security monitoring, digital camera viewfinders, military targeting devices, medical equipment, industrial inspection, and automotive displays [10][11]. Future Outlook - The Micro OLED technology is expected to see further development by 2025, leading to increased investments in upstream core component projects and a more mature industry chain [11].

Group 1 - The Shanghai Composite Index turned positive on May 26, with the Sci-Tech Innovation Index rising by 0.28%, driven by stocks like Kejie Intelligent and Zhongyou Technology, which saw significant gains [1] - The Tianhong Sci-Tech Innovation Index ETF (589860) reported a trading volume exceeding 48 million yuan and a turnover rate of over 5.7%, indicating active trading [1] - The Tianhong ETF experienced a net inflow of 14.73 million yuan on May 23, reflecting investor interest in the Sci-Tech Innovation Index [1] Group 2 - The overall profitability of companies listed on the Sci-Tech Innovation Board is continuously improving, with over 80% of these companies concentrated in high-tech and strategic emerging industries [2] - The average R&D investment of Sci-Tech Innovation Board companies reached 12.64% of their operating income in 2022, totaling 168.08 billion yuan, which is 2.5 times their net profit [2] - Companies with high R&D investment ratios are primarily found in sectors with high technical barriers and long R&D cycles, such as biomedicine, semiconductors, and artificial intelligence [2]

Group 1 - The core viewpoint is that the Chinese innovative drug industry is entering a critical turning point for value reassessment, supported by government policies and the performance of leading companies [1][2] - The Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index has shown mixed performance, with some stocks like Yirui Technology rising over 8% [1] - The Science and Technology Innovation Board Biopharmaceutical Index ETF closely tracks the performance of the biopharmaceutical sector, reflecting the overall performance of representative companies in this industry [1] Group 2 - Century Securities indicates that the innovative drug sector is undergoing a systematic value reassessment, with increasing recognition of domestic innovative drugs by overseas pharmaceutical companies [2] - The industry is transitioning from a phase of capital bubble to a stage where domestic innovations are gaining international recognition, suggesting a significant shift in the market dynamics [2] - Recommendations include focusing on biotech companies with reasonable valuations and differentiated innovation platforms, as well as exploring opportunities in AI-related medical fields [2]

Group 1 - The meeting of the third Supervisory Board was held both on-site and via communication methods, with all three supervisors present and voting [1] - The Supervisory Board approved the proposal for additional related party transactions for the year 2025, stating that the transactions are necessary for the company's business development and comply with legal regulations [1] - The voting result for the proposal was 2 votes in favor, 0 against, and 0 abstentions, with the related supervisor abstaining from the vote [2] Group 2 - The proposal for additional related party transactions will be submitted for approval at the company's shareholders' meeting [2]